Is TARS a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on XDEMVY prescription growth, with revenue (ttm) at ~$540M. The bear case rests on the overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. Analysts covering it are spread from $88.00 to $104.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $88.00, +50.4% from the $58.53 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

XDEMVY prescription growth. XDEMVY net product sales rose more than 85% year over year in Q1 2026 to about $145 million, driven by expanding prescriber adoption and direct-to-consumer campaigns. The most optimistic analyst target on TARS is $104.00, +77.7% from the $58.53 price. That figure is only reachable if this thesis works close to its best case.

The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. In late June 2026, short-seller Culper Research alleged that XDEMVY sales depend on donations routed to a blepharitis copay fund in a way it argues may violate the federal Anti-Kickback Statute, and it claimed the true addressable market is roughly a fifth of company estimates; these are unproven allegations, but they introduce regulatory, reimbursement, and reputational uncertainty. Tarsus also depends on intellectual property licensed from Elanco, faces gross-to-net and Medicare Part D dynamics that can compress net pricing, and still runs near breakeven with a history of losses. Cheaper off-label alternatives and potential future competitors, plus binary Phase 2 pipeline readouts, round out the risk set. The most pessimistic published target is $88.00, +50.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutic eye care.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (XDEMVY prescription growth) stalling in the reported numbers rather than in the narrative, the risk above (the overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Tarsus is a commercial-stage biopharmaceutical company focused on eye care. Its main product, XDEMVY, is the first FDA-approved treatment for Demodex blepharitis, a common eyelid condition caused by mites. It is also developing lotilaner-based candidates for ocular rosacea and Lyme disease prevention.

Almost all revenue comes from XDEMVY net product sales, supplemented by smaller license and collaboration revenue. In Q1 2026 the company reported about $162 million in total revenue, of which roughly $145 million was XDEMVY. Full-year 2025 XDEMVY sales were about $451 million.

Not consistently. The company has a history of losses, though its Q1 2026 net loss narrowed to about $7 million from roughly $25 million a year earlier as XDEMVY revenue scaled against high (about 93%) gross margins. Whether it reaches sustained profitability depends on continued growth versus commercial spending.